OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
April 02, 2020
Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.
As the coronavirus pandemic unfolds, Pharma must practice science over hype.
With ingredients sold to multiple markets, excipient manufacturers must understand the different regulatory requirements for pharma vs. food.
As COVID-19 rapidly spreads, the bio/pharma industry is committing significant efforts to fast track development of therapies.
The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.
March 30, 2020
Pre-clinical immunization studies of iBio’s SARS-CoV-2 VLP candidates are being performed by Texas A&M.
Johnson & Johnson announces clinical trial plans for COVID-19 vaccine candidate, as well as plans to produce 1 billion vaccine doses.
March 27, 2020
AstraZeneca has revealed that it will collaborate with Silence Therapeutics on the discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases.
Grifols has entered into a formal collaboration with US Federal public health agencies, including the Biomedical Advanced Research Development Authority (BARDA) and the Food and Drug Administration (FDA), to produce a treatment that specifically targets COVID-19.
The strategic alliance provides an integrated product offering around drug discovery and development.